Liver and Bile

J Hepatol. 2022;77(3):670–82

Maiwall R, Kumar A, Pasupuleti SSR, Hidam AK, Tevethia H, Kumar G, Sahney A, Mitra LG, Sarin SK

A randomized controlled trial comparing 20%-albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension (ALPS trial)


Background and aims: The choice of resuscitation fluid in patients with cirrhosis and sepsis-induced hypotension is unclear. Five percent-albumin was superior to normal saline in the FRISC study. The authors compared the efficacy and safety of 20%-albumin, which has greater oncotic properties, to plasmalyte in reversing sepsis-induced hypotension.
Methods: Critically ill patients with cirrhosis underwent open-label randomization to receive either 20%-albumin (0.5–1.0 g/kg over 3 hours, n = 50) or plasmalyte (30 ml/kg over 3 hours, n = 50). The primary end point of the study was the attainment of mean arterial pressure (MAP) > 65 mmHg at 3 hours.
Results: Baseline characteristics were comparable in albumin and plasmalyte groups; arterial lactate (6.16 ± 3.18 mmol/l vs. 6.38 ± 4.77 mmol/l; p = 0.78), MAP (51.4 ± 6.52 mmHg vs. 49.9 ± 4.45 mmHg; p = 0.17) and SOFA (sequential organ failure assessment) score (10.8 ± 2.96 vs. 11.1 ± 4.2; p = 0.68), respectively. Most patients were alcoholics (39%) and had pneumonia (40%). In the intention-to-treat analysis, albumin was superior to plasmalyte in achieving the primary end point (62% vs. 22%; p < 0.001). A faster decline in arterial lactate (p = 0.03), a reduced need for dialysis (48% vs. 62%; p = 0.16), and a longer time to initiation of dialysis (in hours) (68.13 ± 47.79 vs. 99.7 ± 63.4; p = 0.06) were seen with albumin. However, the 28-day mortality rate was not different (58% vs. 62%; p = 0.57) and treatment had to be discontinued in 11 patients (22%) in the albumin group due to adverse effects compared to no discontinuations in the plasmalyte group.

Conclusion: In patients with cirrhosis and sepsis-induced hypotension, 20%-albumin leads to a faster improvement in hemodynamics and lactate clearance than plasmalyte, while 28-day survival was similar. However, patients on 20%-albumin need to be closely monitored as it was more often associated with pulmonary complications.

Prof. Dr. S.K. Sarin, Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India,
E-Mail: sksarin@ilbs.in

or

E-Mail: shivsarin@gmail.com

DOI: 10.1016/j.jhep.2022.03.043

Back to overview

this could be of interest:

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

J Hepatol. 2022;77(1):128–39

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

Dig Liver Dis. 2022;54(7):927–36

More articles on the topic